Chugai Pharma USA, Inc., with the slogan "INNOVATION BEYOND IMAGINATION," serves as a vital component of the globally recognized Chugai Pharmaceutical Co., Ltd., originating from Japan. Founded in 1925, Chugai stands among Japan's leading biopharmaceutical companies, excelling in R&D and innovative antibody technologies.
Operating out of Berkeley Heights, NJ, Chugai Pharma USA, Inc. plays a crucial role in strategizing and conducting clinical programs for pioneering drug candidates globally and within the U.S. As a subsidiary, it supports Chugai's mission in addressing unmet medical needs in oncology, bone and joint diseases, renal diseases, and beyond.
Notably, while Chugai independently develops its products until early Proof-of-Concept (PoC), it seeks partnerships for late-stage development and marketing outside Japan, South Korea, and Taiwan. With Roche holding first refusal rights, Chugai solidifies its strategic collaborations to scale global impact.
First entering the public market through an IPO on January 1, 1988, Chugai demonstrates a substantial legacy of innovation and growth, offering a compelling proposition for potential investors seeking a partnership in cutting-edge biotechnology solutions.
